News Conference News TCT 2025 Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2 Todd Neale November 03, 2025
News Conference News TCT 2025 INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time Michael O'Riordan October 29, 2025
News Conference News TCT 2025 Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION Michael O'Riordan October 26, 2025
News Opinion Editor's Corner TCT 2025 What’s Going to Be Hot at TCT 2025 Michael O'Riordan October 09, 2025
News Conference News TCT 2024 SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD L.A. McKeown October 29, 2024
News Opinion Editor's Corner TCT 2024 What’s Going to Be Big at TCT 2024? Michael O'Riordan October 17, 2024
News Conference News TCT 2021 OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions L.A. McKeown October 25, 2021
News Conference News TCT 2021 Good Long-term Results With FANTOM BVS, but More Data Needed Michael O'Riordan October 21, 2021
Presentation TCT 2020 Featured Clinical Research: (TCT36010) MOTIV BTK Pilot Study – Initial Safety and Performance Study of the MOTIV Sirolimus-Eluting Bioresorbable Coronary Scaffold; Initial Report on First 10 Patients Presenter: Michel Bosiers October 15, 2020
News Conference News TCT 2018 CORRECTION: Polymer-Free BioFreedom Stent Faces Off Against Orsiro Michael O'Riordan September 22, 2018
Presentation TCT 2016 TCT 261: Impact of Diabetes on Clinical Outcomes after Revascularization with Sirolimus-Eluting and Birolimus-Eluting Stents with Biodegradable Polymer. From the SORT OUT VII Trial Presenter: Kevin J. Beatt, Frederick Feit October 31, 2016